Sun Pharma Q3 numbers likely to surge

IIFL forecasts the company’s net profit for Q3 FY16 to jump 40%.

Sun Pharmaceuticals will announce its financial results on February 12 for the third quarter ended December 31, 2015.

IIFL expects net revenue to rise at a rate of 14.5% yoy. IIFL forecasts the company’s net profit for Q3 FY16 to jump 40%.

Sun Pharma Q3 revenues would be impacted due to continued pressure on US supplies due to Halol remediation and pressure on base business as evidenced in Q2 results; we expect adjusted US revenues (for US$40mn one off income in Q2) to decline 1.5% qoq while domestic revenues would inch up 1.5% qoq. Overall we expect 2.7% revenue decline leading to concurrent pressure on margins (‐130bps qoq) and ~17% sequential decline in PAT. We expect InSite acquisition to be factored in Q3 and would look for management commentary on Halol, Ranbaxy integration and US business outlook

Other key Q3 results on February 12 include Adani Ports & SEZ, Adani Power, Apollo Hospitals, BPCL, ITDC, IOCL, Kolte Patil, Man Industries, M&M, Marksans Pharma, Nestle, NMDC, Punj Lloyd, Shakti Pump, Rashtriya Chemicals, Repro India, Shilpa Medicare, Suven Lifesciences and Sun TV.